H.C. Wainwright notes that Vivani Medical (VANI) has announced positive preclinical data for NPM-139, a subdermal semaglutide implant being developed for chronic weight management. In the firm’s view, the preclinical data validates the versatility of the company’s NanoPortal technology platform. Management noted that the ongoing Phase 1 trial of NPM-115 is on track to report topline data in mid-2025, which would provide insights to support further development of NPM-115 as well as NPM-139. H.C. Wainwright reiterate a Buy rating on the shares with a price target of $4.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VANI:
- Vivani Medical’s Innovative Implants and Promising Trials Justify Buy Rating
- Vivani Medical announces preclinical weight loss data for NPM-139
- VANI Earnings this Week: How Will it Perform?
- Vivani Medical’s Innovative Drug Delivery Platform and Promising Developments Earn Buy Rating
- Vivani Medical Advances with LIBERATE-1 Clinical Trial